Drug intelligence / Profile preview

ATTO-008

Development stage: Preclinical
Lead developer: Attovia Therapeutics
Modality: Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

ATTO-008 is a preclinical-stage, tri- or tetra-specific multi-alarmin blocker being developed by Attovia Therapeutics for the treatment of respiratory diseases, including asthma (specifically Th2-low asthma) and chronic obstructive pulmonary disease (COPD). Discovered using Attovia's proprietary ATTOBODY™ biparatopic biologics platform, ATTO-008 is designed to simultaneously target and inhibit multiple alarmins—innate immune danger signals that drive airway inflammation. By blocking these upstream inflammatory pathways, the candidate aims to provide a more comprehensive therapeutic effect compared to single-pathway biologics.

Beyond the preview

Go deeper on ATTO-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATTO-008.

Explore the full profile